

BOSTON SCIENTIFIC CORP  
Form 8-K  
February 26, 2007

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

---

Date of Report (Date of earliest event reported): February 20, 2007

**BOSTON SCIENTIFIC CORPORATION**  
(Exact name of registrant as specified in charter)

**DELAWARE**  
(State or other  
jurisdiction of  
incorporation)

**1-11083**  
(Commission  
file number)

**04-2695240**  
(IRS employer  
identification no.)

**One Boston Scientific Place, Natick, Massachusetts**  
(Address of principal executive offices)

**01760-1537**  
(Zip code)

Registrant's telephone number, including area code: **(508) 650-8000**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ..  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.**

***Retention Agreement***

On February 20, 2007, the Compensation Committee of the Board of Directors of Boston Scientific Corporation (the “Company”) approved an amendment to the definition of “Change in Control” contained in the Retention Agreement between the Company and each of its executive officers to mean the consummation of a reorganization, merger, consolidation or similar arrangement involving the Company, rather than the shareholder approval of such a transaction. We intend to ask each executive officer to sign an amended Retention Agreement. A copy of the form of Retention Agreement, as amended, is filed with this report as Exhibit 10.1.

***2007 Performance Incentive Plan***

On February 20, 2007, the Compensation Committee of the Board of Directors of the Company approved an amendment to the 2007 Performance Incentive Plan, which plan is applicable to its executive officers, establishing an incentive compensation recoupment policy. In the event of a restatement of the financial statements of the Company that would reduce a previously granted award’s size or payment, the Company will seek reimbursement of the amount of the performance incentive award paid to the Company’s executive officers which is in excess of the amounts that would have been paid based on the restated financial results. A copy of the 2007 Performance Incentive Plan, as amended, is filed with this report as Exhibit 10.2.

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
10.1	Form of Retention Agreement, as amended.
10.2	2007 Performance Incentive Plan, as amended.

**SIGNATURE**

Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BOSTON SCIENTIFIC CORPORATION**

Date: February 26, 2007

By: /s/ Lawrence J. Knopf

\_\_\_\_\_  
Lawrence J. Knopf  
Vice President and Assistant General Counsel

**INDEX TO EXHIBITS**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
10.1	Form of Retention Agreement, as amended.
10.2	2007 Performance Incentive Plan, as amended.

-4-

---